Steck Mackenzie, Wells Drew A, Stoffel Jaclyn M, Hudson Joanna Q, Saeed Omar, Elangovan Cheran, Krishnaiah Balaji, Shah Samarth P
Department of Pharmacy, Indiana University Health - University Hospital, Indianapolis, IN, USA.
Department of Pharmacy, Methodist Le Bonheur Healthcare - University Hospital, Memphis, TN, USA.
Neurohospitalist. 2024 Oct;14(4):373-378. doi: 10.1177/19418744231200048. Epub 2023 Sep 19.
Hyperglycemia following acute ischemic stroke (AIS) is associated with adverse outcomes including, hemorrhagic conversion and increased length of stay; however, the impact of glycemic variability is largely unknown. This study aims to evaluate the effect of glycemic variability on discharge outcomes in patients treated with alteplase for AIS.
A retrospective review of ischemic stroke patients who presented within 4.5 hours from symptom onset and received alteplase was completed. Patients hospitalized for at least 48 hours were included. Glycemic variability was measured using J-index. Groups were defined by normal or abnormal J-indices. Logistic regression models were developed to determine odds ratios for select clinical characteristics, NIHSS score, mRS, and disposition at discharge.
Of the 229 patients, 97 (42%) had an abnormal J-index. In the univariate analysis, abnormal J-index was associated with worse outcomes in terms of NIHSS score, mRS, and discharge disposition compared to a normal J-index. In the unadjusted multivariate analysis, abnormal J-index was associated with higher odds of unfavorable mRS (3-6) at discharge (OR 2.1; 95% CI 1.2 - 3.5, = .009). In the adjusted multivariate analysis, patients with an abnormal J-index had higher odds of hemorrhagic transformation (OR 5.7; 95% CI 2.1 - 15.6, < .0001). There was no difference in mortality.
Glycemic variability with abnormal J-index following AIS is associated with adverse functional outcomes at discharge and increased odds of hemorrhagic conversion in patients treated with alteplase. Additional studies validating glycemic variability indices post-ischemic stroke are needed to determine the full clinical impact.
急性缺血性卒中(AIS)后的高血糖与包括出血性转化和住院时间延长在内的不良预后相关;然而,血糖变异性的影响在很大程度上尚不清楚。本研究旨在评估血糖变异性对接受阿替普酶治疗的AIS患者出院结局的影响。
对症状发作后4.5小时内就诊并接受阿替普酶治疗的缺血性卒中患者进行回顾性研究。纳入住院至少48小时的患者。使用J指数测量血糖变异性。根据J指数正常或异常对患者进行分组。建立逻辑回归模型以确定选定临床特征、美国国立卫生研究院卒中量表(NIHSS)评分、改良Rankin量表(mRS)及出院时处置方式的比值比。
229例患者中,97例(42%)J指数异常。在单因素分析中,与J指数正常相比,J指数异常在NIHSS评分、mRS及出院处置方面的结局更差。在未校正的多因素分析中,J指数异常与出院时mRS评分不良(3 - 6分)的较高几率相关(比值比2.1;95%置信区间1.2 - 3.5,P = .009)。在校正的多因素分析中,J指数异常的患者发生出血性转化的几率更高(比值比5.7;95%置信区间2.1 - 15.6,P < .0001)。死亡率无差异。
AIS后J指数异常的血糖变异性与接受阿替普酶治疗患者出院时的不良功能结局及出血性转化几率增加相关。需要进一步研究验证缺血性卒中后血糖变异性指标以确定其全部临床影响。